psalexa
logo

Immunoglobulin A (IgA) Nephropathy Therapeutics - Pipeline Analysis and Epidemiology Forecast

Immunoglobulin A (IgA) Nephropathy Therapeutics - Pipeline Analysis, Clinical Trials & Results, Patents, Designations, Collaborations, Patient Size, and Epidemiology Forecast to 2025

Published: March 2018
Report Code: LS10912
Available Format:
Pages: 130

Note: This report can also be updated as of date and delivered within 1-2 workings days of purchase confirmation

Chapter 1. Research Background

1.1 Research Objectives

1.2 Definition

1.3 Research Scope

1.3.1 Pipeline Analysis by Phase

1.3.2 Pipeline Analysis by Molecule Type

1.3.3 Pipeline Analysis by Route of Administration

1.4 Key Stakeholders

Chapter 2. Research Methodology

2.1 Secondary Research

2.1.1 Secondary Sources for Epidemiology Analysis

2.2 Primary Research

2.2.1 Breakdown of Primary Research Respondents

2.2.1.1 By industry participant

2.2.1.2 By company type

2.2.2 KOLs Validation

2.3 Coverage of Epidemiology Analysis

2.4 Forecast Methodology for Epidemiology Analysis

2.5 Assumptions for Epidemiology Analysis

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook

4.1 Disease Overview

4.2 Causes

4.3 Signs and Symptoms

4.4 Pathophysiology

4.5 Diagnosis

4.6 Treatment

4.7 Epidemiology

4.8 Key Drivers

4.8.1 No Specific Treatment

4.8.2 Driver 2

4.9 Key Barrier

4.9.1 No Early Signs or Symptoms

4.1 IgA Nephropathy Therapeutics Pipeline Analysis

4.10.1 Pipeline Analysis by Phase

4.10.2 Pipeline Analysis by Molecule Type

4.10.3 Pipeline Analysis by Route of Administration

4.10.4 Pipeline Analysis by Company

Chapter 5. IgA Nephropathy Epidemiology Overview

5.1 IgA Nephropathy Epidemiology Forecast for 7MM

5.1.1 IgA Nephropathy Epidemiology Forecast for the U.S.

5.1.2 IgA Nephropathy Epidemiology Forecast for Japan

5.1.3 IgA Nephropathy Epidemiology Forecast for EU5

5.1.3.1 IgA nephropathy epidemiology for the U.K.

5.1.3.2 IgA nephropathy epidemiology for Germany

5.1.3.3 IgA nephropathy epidemiology for France

5.1.3.4 IgA nephropathy epidemiology for Italy

5.1.3.5 IgA nephropathy epidemiology for Spain

Chapter 6. Immunoglobulin A (IgA) Nephropathy Therapeutics Pipeline Analysis by Phase (2018)

6.1 Phase III

6.1.1 ACTH (Acthar) Gel

6.1.1.1 Clinical trials

6.1.1.2 Clinical results

6.1.1.3 Strategic development

6.1.2 XXXX

6.1.2.1 Clinical trials

6.1.2.2 Clinical results

6.1.2.3 Strategic development

6.1.2.4 Designation

6.1.2.5 Patent

6.1.2.6 Financing

6.1.2.7 Technology

6.1.3 XXXX

6.1.3.1 Clinical trials

6.1.3.2 Clinical results

6.1.3.3 Strategic development

6.2 Phase II/III

6.2.1 XXXX

6.2.1.1 Clinical trials

6.2.1.2 Clinical results

6.2.1.3 Strategic development

6.3 Phase II

6.3.1 Atacicept

6.3.1.1 Clinical trials

6.3.2 XXXX

6.3.2.1 Clinical trials

6.3.2.2 Clinical results

6.3.3 XXXX

6.3.3.1 Clinical trials

6.3.4 XXXX

6.3.4.1 Clinical trials

6.3.5 XXXX

6.3.5.1 Clinical trials

6.3.6 XXXX

6.3.6.1 Clinical trials

6.3.6.2 Strategic development

6.4 Pre-Clinical

6.4.1 IgA Protease

6.4.1.1 Grant

6.4.2 XXXX

6.4.3 XXXX

6.4.3.1 Pre- Clinical study

6.4.3.2 Strategic development

6.4.3.3 Technology

6.4.4 XXXX

6.5 Unknown

6.5.1 IL-6 antibody

6.5.1.1 Patent

6.5.2 XXXX

6.5.3 XXXX

6.6 Discovery

6.6.1 XXXX

6.7 Inactive

6.7.1 XXXX

6.7.1.1 Clinical trials

6.7.1.2 Strategic development

6.7.2 XXXX

6.7.2.1 Clinical trials

6.7.3 XXXX

6.7.3.1 Clinical trials

6.7.4 XXXX

6.7.4.1 Clinical trials

6.8 Discontinued

6.8.1 XXXX

6.8.1.1 Clinical trials

6.8.2 XXXX

Chapter 7. Clinical Trials Review

7.1 Clinical Trials by Region

7.2 Clinical Trials by Trial Status

Chapter 8. Competitive Landscape

8.1 Key Player Benchmarking

8.2 SWOT Analysis of IgA Nephropathy Pipeline

Chapter 9. Company Profiles

9.1 Mallinckrodt plc

9.1.1 Business Overview

9.1.2 Product Offerings

9.2 Company 2

9.2.1 Business Overview

9.2.2 Product Offerings

9.3 Company 3

9.3.1 Business Overview

9.3.2 Product Offerings

9.4 Company 4

9.4.1 Business Overview

9.4.2 Product Offerings

9.5 Company 5

9.5.1 Business Overview

9.5.2 Product Offerings

9.6 Company 6

9.6.1 Business Overview

9.6.2 Product Offerings

9.7 Company 7

9.7.1 Business Overview

9.7.2 Product Offerings

9.8 Company 8

9.8.1 Business Overview

9.8.2 Product Offerings

Chapter 10. Appendix

10.1 Abbreviation

10.2 Related Reports

 

LIST OF TABLES

 

TABLE 1 PIPELINE ANALYSIS OF IGA NEPHROPATHY THERAPEUTICS, BY COMPANY (2018)

TABLE 2 IGA NEPHROPATHY EPIDEMIOLOGY FOR 7MM (2016-2025)

TABLE 3 IGA NEPHROPATHY EPIDEMIOLOGY FOR THE U.S. (2016-2025)

TABLE 4 IGA NEPHROPATHY EPIDEMIOLOGY FORECAST FOR JAPAN (2016-2025)

TABLE 5 IGA NEPHROPATHY EPIDEMIOLOGY FOR EU5 (2016-2025)

TABLE 6 IGA NEPHROPATHY EPIDEMIOLOGY FOR THE U.K (2016-2025)

TABLE 7 IGA NEPHROPATHY EPIDEMIOLOGY FOR GERMANY (2016-2025)

TABLE 8 IGA NEPHROPATHY EPIDEMIOLOGY FOR FRANCE (2016-2025)

TABLE 9 IGA NEPHROPATHY EPIDEMIOLOGY FOR ITALY (2016-2025)

TABLE 10 IGA NEPHROPATHY EPIDEMIOLOGY FOR SPAIN (2016-2025)

TABLE 11 DESCRIPTION OF ACTH (ACTHAR) GEL

TABLE 12 CLINICAL TRIALS OF ACTH (ACTHAR) GEL

TABLE 13 DESCRIPTION OF XXXX

TABLE 14 CLINICAL TRIALS OF XXXX

TABLE 15 DESCRIPTION OF XXXX

TABLE 16 CLINICAL TRIALS OF XXXX

TABLE 17 DESCRIPTION OF XXXX

TABLE 18 CLINICAL TRIALS OF XXXX

TABLE 19 DESCRIPTION OF ATACICEPT

TABLE 20 CLINICAL TRIALS OF ATACICEPT

TABLE 21 DESCRIPTION OF XXXX

TABLE 22 CLINICAL TRIALS OF XXXX

TABLE 23 DESCRIPTION OF XXXX

TABLE 24 CLINICAL TRIALS OF XXXX

TABLE 25 DESCRIPTION OF XXXX

TABLE 26 CLINICAL TRIALS OF XXXX

TABLE 27 DESCRIPTION OF XXXX

TABLE 28 CLINICAL TRIALS OF XXXX

TABLE 29 DESCRIPTION OF XXXX

TABLE 30 CLINICAL TRIALS OF XXXX

TABLE 31 DESCRIPTION OF IGA PROTEASE

TABLE 32 DESCRIPTION OF XXXX

TABLE 33 DESCRIPTION OF XXXX

TABLE 34 DESCRIPTION OF XXXX

TABLE 35 DESCRIPTION OF IL-6 ANTIBODY

TABLE 36 DESCRIPTION OF XXXX

TABLE 37 DESCRIPTION OF XXXX

TABLE 38 DESCRIPTION OF XXXX

TABLE 39 DESCRIPTION OF XXXX

TABLE 40 CLINICAL TRIALS OF XXXX

TABLE 41 DESCRIPTION OF XXXX

TABLE 42 CLINICAL TRIALS OF XXXX

TABLE 43 DESCRIPTION OF XXXX

TABLE 44 CLINICAL TRIALS OF XXXX

TABLE 45 DESCRIPTION OF XXXX

TABLE 46 CLINICAL TRIALS OF XXXX

TABLE 47 DESCRIPTION OF XXXX

TABLE 48 CLINICAL TRIALS OF XXXX

TABLE 49 DESCRIPTION OF XXXX

TABLE 50 CLINICAL TRIALS OF XXXX

TABLE 51 MALLINCKRODT PLC – AT A GLANCE

TABLE 52 COMPANY 2 – AT A GLANCE

TABLE 53 COMPANY 3 – AT A GLANCE

TABLE 54 COMPANY 4 – AT A GLANCE

TABLE 55 COMPANY 5 – AT A GLANCE

TABLE 56 COMPANY 6 – AT A GLANCE

TABLE 57 COMPANY 7 – AT A GLANCE

TABLE 58 COMPANY 8 – AT A GLANCE

 

LIST OF FIGURES

 

FIG 1: RESEARCH METHODOLOGY

FIG 2: BREAKDOWN OF PRIMARY RESEARCH RESPONDENTS, BY INDUSTRY PARTICIPANT

FIG 3: BREAKDOWN OF PRIMARY RESEARCH RESPONDENTS, BY COMPANY TYPE

FIG 4: PATHOPHYSIOLOGY OF IGA NEPHROPATHY

FIG 5: TREATMENT ALGORITHM OF IGA NEPHROPATHY

FIG 6: IGA NEPHROPATHY DRUG CANDIDATES UNDER DEVELOPMENT (2018)

FIG 7: IGA NEPHROPATHY PIPELINE SPLIT, BY MOLECULE TYPE (2018)

FIG 8: IGA NEPHROPATHY PIPELINE SPLIT, BY ROUTE OF ADMINISTRATION (2018)

FIG 9: TOTAL NUMBER OF PREVALENT CASES FOR 7MM (2016 & 2025)

FIG 10: IGA NEPHROPATHY PREVALENCE RATE IN 7MM (2016-2025)

FIG 11: IGA NEPHROPATHY EPIDEMIOLOGY FOR 7MM (2016-2025)

FIG 12: IGA NEPHROPATHY EPIDEMIOLOGY FOR THE U.S. (2016-2025)

FIG 13: IGA NEPHROPATHY EPIDEMIOLOGY FORECAST FOR JAPAN (2016-2025)

FIG 14: IGA NEPHROPATHY EPIDEMIOLOGY FOR EU5 (2016-2025)

FIG 15: IGA NEPHROPATHY EPIDEMIOLOGY FOR THE U.K. (2016-2025)

FIG 16: IGA NEPHROPATHY EPIDEMIOLOGY FOR GERMANY (2016-2025)

FIG 17: IGA NEPHROPATHY EPIDEMIOLOGY FOR FRANCE (2016-2025)

FIG 18: IGA NEPHROPATHY EPIDEMIOLOGY FOR ITALY (2016-2025)

FIG 19: IGA NEPHROPATHY EPIDEMIOLOGY FOR SPAIN (2016-2025)

FIG 20: PHASE II RESULTS OF XXXX XXXX XXXX XXXX XXXX XXXX XXXX XXXX XXXX XXXX XXXX XXXX XXXX

FIG 21: PHASE II RESULTS OF XXXX XXXX XXXX XXXX XXXX XXXX XXXX XXXX XXXX XXXX XXXX

FIG 22: PHASE II AND FOLLOW-UP RESULTS XXXX XXXX XXXX

FIG 23: BREAKDOWN OF CLINICAL TRIALS, BY REGION

FIG 24: BREAKDOWN OF CLINICAL TRIALS, BY TRIAL STATUS

FIG 25: KEY PLAYER BENCHMARKING

FIG 26: SWOT ANALYSIS OF IGA NEPHROPATHY PIPELINE

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 3250
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 4000
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 7750

Pre-Purchase Enquiry